Fig. 2. Chronic treatment of immature female rats with [HisLys6]GHRP. Initially immature female rats (16 d of age) were distributed among the mothers so that the BW in groups A and B would be the same, and treatment with saline (A) or the peptide (B) was started the next day. Saline or the peptide (50 ^g) was injected sc daily at 1500 h for 25 d. Mean of 20 ± SEM. P values of treated vs untreated control group (A). *p < 0.01, **p < 0.02, ***p < 0.05. Reproduced with permission from ref. 11.
synergism was even greater (Fig. 3A). Regardless of the apparent independent action of the three secretagogues, pretreatment with GHRH anti-serum markedly inhibited the GH response of each one of them (Fig. 3B). Complementary studies with somatotropin-release inhibiting factor (SRIF) antiserum pretreatment indicated that it increased the GH response to GHRP-6 and GHRH but not to the benzomorphan opiate 2549 or the opiate
Fig. 3. (A) In vivo studies on the synergistic release of GH in conscious 26-d-old female rats. At zero time, saline, 10 ^g GHRP, 10 ^g GHRH, 10 ^g 2549 opiate, and/or 100 ^g dermorphin (DM) were injected iv, and rats were killed at +10 min. Each value represents the mean of 6 ± SEM; P values are given for treated vs saline. *p < 0.02, **p < 0.01, ***p < 0.001. When P values were determined for the various groups vs GHRP, GHRH, plus dermorphin or 2549, the values ranged
Was this article helpful?